118 related articles for article (PubMed ID: 38497241)
1. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Bornstein SR; de Zeeuw D; Heerspink HJL; Schulze F; Cronin L; Wenz A; Tuttle KR; Hadjadj S; Rossing P
Diabetes Obes Metab; 2024 Jun; 26(6):2128-2138. PubMed ID: 38497241
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR; Hauske SJ; Canziani ME; Caramori ML; Cherney D; Cronin L; Heerspink HJL; Hugo C; Nangaku M; Rotter RC; Silva A; Shah SV; Sun Z; Urbach D; de Zeeuw D; Rossing P;
Lancet; 2024 Jan; 403(10424):379-390. PubMed ID: 38109916
[TBL] [Abstract][Full Text] [Related]
3. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
4. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
5. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Cherney DZI; de Zeeuw D; Heerspink HJL; Cardona J; Desch M; Wenz A; Schulze F; Nangaku M
Diabetes Obes Metab; 2023 Aug; 25(8):2218-2226. PubMed ID: 37232058
[TBL] [Abstract][Full Text] [Related]
7. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
8. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
9. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
[TBL] [Abstract][Full Text] [Related]
11. Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.
Tuttle KR; Rossing P; Hauske SJ; Cronin L; Hussain J; de Zeeuw D; Heerspink HJL
Am J Nephrol; 2024; 55(2):262-272. PubMed ID: 37903483
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
14. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
16. Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial).
Johansen ML; Schou M; Rossignol P; Holm MR; Rasmussen J; Brandt N; Frandsen M; Chabanova E; Dela F; Faber J; Kistorp C
Diabetes Obes Metab; 2019 Oct; 21(10):2305-2314. PubMed ID: 31183945
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
[TBL] [Abstract][Full Text] [Related]
19. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
Mårup FH; Peters CD; Christensen JH; Birn H
BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
[TBL] [Abstract][Full Text] [Related]
20. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
